Koda for Clinicians is now available in Connection Hub on Epic Showroom. AI-enhanced Advance Care Planning platform expands access for health systems nationwide HOUSTON, TX, UNITED STATES, July 15, 2026 /EINPresswire.com/ - Koda Health, the AI-enhanced Advance Care Planning (ACP) platform, announced today that Koda for Clinicians is listed in Epic Connection Hub, giving health systems, hospitals, ACOs, and population health organizations a direct path to discover and deploy Koda's ACP solution within their existing clinical workflows. The announcement comes at a pivotal moment as CMS advances new quality measures tied to advance care planning. The FY2027 IPPS proposed rule adds the Advance Care Planning eCQM, while its parent measure (MUC2025-020) is under consideration for adoption across additional care settings, including home health, skilled nursing, ambulatory surgery centers, and dialysis. Combined with CMS's public reporting of the Age-Friendly Hospital measure on goals-of-care conversations, the direction is clear: advance care planning is no longer optional infrastructure, but an emerging core accountability metric for health systems. Koda for Clinicians is a SMART-on-FHIR application that embeds directly within Epic, enabling care teams to initiate ACP referrals, track patient progress in real time, and access completed legal documents, including key discrete data elements, without leaving the patient chart. Completed goals, values, preferences, and advance directives are automatically written back to the chart via HL7v2, with clear version control that distinguishes active plans from revoked ones. Beyond document access, Koda surfaces key elements of Medical Power of Attorney and Living Will information as discrete data fields and flags both the documents and the underlying fields as legally valid and signed, which gives clinicians a fast view of critical decision-making details during time sensitive situations. Patients can access Koda through single sign-on using their existing MyChart credentials. "Health systems already know they need to scale advance care planning, but finding the right tools to do it is the hard part," said Dr. Tatiana Fofanova, CEO and Co-Founder of Koda Health. "With CMS raising the bar through new quality measures, the window to build this infrastructure is now. Connection Hub on Epic Showroom puts Koda in front of the organizations actively looking to solve that problem, closing the gap between the care patients receive and the care they actually want." Koda is the only advance care planning solution with published evidence demonstrating reductions in inpatient utilization, ICU length of stay, and total cost of care. Its platform supports the full ACP journey, from guided patient education and decision-making to legally valid documentation and seamless EHR integration, and has demonstrated measurable outcomes across its health system and payer partners: - 85% of users complete their ACP - 4x the national average - Average cost savings of $10,000-$15,000 per patient - Patient Net Promoter Score (NPS) of 87 Koda's largest Epic integration deployment supports one of the world's leading cancer centers, giving more than 175,000 patients and 2,000 clinicians seamless access to ACP infrastructure directly within Epic. Koda Health currently serves over 1 million patients nationwide and partners with leading health systems and payers including Healthspring, Memorial Hermann, Houston Methodist, and Guidehealth. Epic and MyChart are registered trademarks of Epic Systems Corporation. About Koda Health Koda Health is an AI-enhanced patient decision support platform that enables health systems and payors to efficiently scale goals-of-care conversations, aligning treatment with patient preferences to reduce unwanted utilization. To learn more about Koda, visit www.kodahealthcare.com Kamila Khasanova On Top Strategy [email protected] Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Koda Health and UPMC Enterprises Collaborate | Click Therapeutics and Boehringer Ingelheim Announce Series D. April 30, 2026 Check out today's featured companies who have recently raised a round of funding, and be sure to check out the full list of past healthcare IT fundings. Koda Health and UPMC Enterprises Collaborate to Prove Out the Value of Advance Care Planning (ACP) at Scale Backed by Strategic Investment from UPMC Enterprises, Koda Health Scales AI-Enhanced Advance Care Planning Across Complex Populations Koda Health, an AI-enhanced Advance Care Planning (ACP) platform, today announced a strategic investment from UPMC Enterprises as part of the company's Series A raise. The investment reflects UPMC Enterprises' conviction that digitally guided, values-based advance care planning represents a critical and underbuilt layer of serious illness infrastructure. Koda's platform guides patients through condition-specific care planning conversations via video and guided education, helping them document their values, care wishes, medical decision-makers, and treatment preferences. High acuity patients are paired with a dedicated Koda Member Advocate - a clinician with a background in palliative nursing or social work - who provides longitudinal support throughout the care planning process. These advocates ensure advance care plans are complete, surrogates are aligned, and that members receive the care that matters most to them during serious illness. Patient preferences flow directly into clinical workflows, ensuring care teams have access to patient goals at the moments that matter most. An estimated $200 billion is spent each year on care that patients would not have wanted had they been engaged in their care planning earlier. ACP is proven to close that gap, but has historically been difficult to deliver at scale. Koda Health has demonstrated a 79% reduction in terminal hospitalizations, a 38% reduction in ICU utilization, and a 19% reduction in total cost of care for patients in the last year of life in a third-party validated study. "UPMC Enterprises' investment is a meaningful signal, not just to Koda, but to the broader market. It validates that health systems are ready to invest in infrastructure that makes advance care planning work the way it should: proactively, at scale, and with the human support that these conversations require. Having UPMC Enterprises as a strategic investor puts us in a unique position to prove what's possible," said Dr. Desh Mohan, Co-Founder and Chief Medical Officer at Koda Health. "UPMC Enterprises invests in companies building infrastructure that improves how care is delivered for patients who need it most," said Kathryn Heffernan, Senior Director at UPMC Enterprises... Click Therapeutics and Boehringer Ingelheim Announce Series D Investment and Funding to Advance Commercialization of CT-155 * The Financing Combines a $50M Series D Investment by Boehringer Ingelheim with Additional Dedicated Funding to Support Commercialization; As Part of the Agreement, Boehringer is Transferring Responsibility for Commercializing CT-155 to Click Therapeutics * Granted Breakthrough Device Designation by the FDA in 2024, the CT-155 Phase III CONVOKE Study was the First and Only Pivotal Trial to Show a Statistically Significant Reduction in Experiential Negative Symptoms of Schizophrenia as an Adjunct to Standard of Care Antipsychotic Treatment * Treatment with CT-155 Demonstrated a Cohen's D Effect Size of -0.36 (p Value= 0.0003) Reflective of a 6.8-Point Improvement of Negative Symptoms Severity as Measured by CAINS-MAP at 16 Weeks (vs. 4.2-Point in Digital Control Arm), Representing a 62% Relative Improvement * Click Therapeutics' Expertise in Digital Therapeutics, Experience in the Mental Health Space, and Commitment to Patient-Centric Approaches Position the Company Well to Bring this Important Therapy to Patients Boehringer Ingelheim and Click Therapeutics today announced a strategic agreement to support the commercialization of CT-155, an investigational prescription digital therapeutic that is being studied for the treatment of the experiential negative symptoms of schizophrenia in adults aged 18 years and older. Under the agreement, Boehringer will transfer full product responsibility, including all commercial and marketing authorization rights, to Click Therapeutics. To support this transition, Boehringer has made a $50M Series D strategic investment and provided dedicated commercial funding to help bring CT-155 to patients, if cleared by the FDA. CT-155 was co-developed by Boehringer and Click. "Boehringer Ingelheim's selection of Click to deliver CT-155 to patients is powerful validation of our vision and the capabilities we have spent over a decade building," said David Benshoof Klein, CEO and founder of Click Therapeutics. "We are eager to take the lead with CT-155 and are focused on getting this FDA-designated Breakthrough Device to patients after clearance by the FDA." The study met its primary endpoint, as presented at the 38th Annual European College of Neuropsychopharmacology (ECNP) Congress, which was change in experiential negative symptoms from baseline to 16 weeks as measured by the Clinical Assessment Interview for Negative Symptoms, Motivation and Pleasure Scale (CAINS-MAP). Treatment with CT-155 demonstrated a Cohen's D effect size of -0.36 (p value= 0.0003) reflective of a 6.8-point improvement of negative symptoms severity as measured by CAINS-MAP at 16 weeks (vs. 4.2-point in digital control arm), representing a 62% relative improvement. CT-155 was well-tolerated and demonstrated an adverse event (AE) profile consistent with past studies. The AE rates with CT-155 and the digital control arm were 8.3% vs 13.4%, respectively. There were no trial discontinuations attributed to CT-155 and two (2) for the digital control arm. There were no serious AEs related to either group... Get Fresh Healthcare & IT Stories Delivered Daily